title: Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients.
abstract: BACKGROUND
  Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive malignancy, characterized by largely unsatisfactory responses to the currently available therapeutic strategies. In this study we evaluated the expression of genes involved in gemcitabine uptake in a selected cohort of patients with PDAC, with well-defined clinical-pathological features.
  
  
  METHODS
  mRNA levels of hENT1, CHOP, MRP1 and DCK were evaluated by means of qRT-PCR in matched pairs of tumor and adjacent normal tissue samples collected from PDAC patients treated with gemcitabine after surgical tumor resection. To detect possible interaction between gene expression levels and to identify subgroups of patients at different mortality/progression risk, the RECursive Partitioning and Amalgamation (RECPAM) method was used.
  
  
  RESULTS
  RECPAM analysis showed that DCK and CHOP were most relevant variables for the identification of patients with different mortality risk, while hENT1 and CHOP were able to identify subgroups of patients with different disease progression risk.
  
  
  CONCLUSIONS
  hENT1, CHOP, MRP1 and DCK appear correlated to PDAC, and this interaction might influence disease behavior.
authors.forename: Francesca
authors.initials: F
authors.lastname: Tavano
authors.forename: Andrea
authors.initials: A
authors.lastname: Fontana
authors.forename: Fabio
authors.initials: F
authors.lastname: Pellegrini
authors.forename: Francesca Paola
authors.initials: FP
authors.lastname: Burbaci
authors.forename: Francesca
authors.initials: F
authors.lastname: Rappa
authors.forename: Francesco
authors.initials: F
authors.lastname: Cappello
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Copetti
authors.forename: Evaristo
authors.initials: E
authors.lastname: Maiello
authors.forename: Lucia
authors.initials: L
authors.lastname: Lombardi
authors.forename: Paolo
authors.initials: P
authors.lastname: Graziano
authors.forename: Manlio
authors.initials: M
authors.lastname: Vinciguerra
authors.forename: Fabio Francesco
authors.initials: FF
authors.lastname: di Mola
authors.forename: Pierluigi
authors.initials: P
authors.lastname: di Sebastiano
authors.forename: Angelo
authors.initials: A
authors.lastname: Andriulli
authors.forename: Valerio
authors.initials: V
authors.lastname: Pazienza
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D021441:Carcinoma, Pancreatic Ductal / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D015331:Cohort Studies; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018450:Disease Progression; D033721:Equilibrative Nucleoside Transporter 1 / Q000235:genetics / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics; D015996:Survival Rate; D051742:Transcription Factor CHOP / Q000235:genetics; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D003841:Deoxycytidine; D033721:Equilibrative Nucleoside Transporter 1; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D012333:RNA, Messenger; D051742:Transcription Factor CHOP; D000093542:Gemcitabine; C497249:DDIT3 protein, human; C438649:SLC29A1 protein, human; C421109:multidrug resistance-associated protein 1